AstraZeneca plc (NYSE:AZN) – Research analysts at Jefferies Financial Group lifted their Q2 2020 earnings estimates for shares of AstraZeneca in a research report issued to clients and investors on Thursday, July 9th. Jefferies Financial Group analyst P. Welford now expects that the company will earn $0.41 per share for the quarter, up from their previous forecast of $0.40. Jefferies Financial Group also issued estimates for AstraZeneca’s FY2021 earnings at $2.45 EPS and FY2022 earnings at $3.11 EPS.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.06. AstraZeneca had a return on equity of 33.97% and a net margin of 5.94%. The business had revenue of $6.35 billion for the quarter, compared to the consensus estimate of $5.95 billion. During the same period last year, the business posted $0.89 EPS. The business’s revenue was up 16.3% compared to the same quarter last year.

Other research analysts also recently issued reports about the company. FIG Partners initiated coverage on AstraZeneca in a research note on Thursday, April 23rd. They set a “reduce” rating on the stock. Zacks Investment Research upgraded AstraZeneca from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a research note on Monday, June 15th. Oddo Bhf downgraded AstraZeneca from a “buy” rating to a “reduce” rating in a research note on Wednesday, June 24th. Cowen boosted their target price on AstraZeneca from $55.00 to $60.00 in a research note on Wednesday, June 10th. Finally, UBS Group restated a “sell” rating on shares of AstraZeneca in a research note on Thursday, June 4th. Four analysts have rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. AstraZeneca presently has a consensus rating of “Hold” and a consensus target price of $59.75.

Shares of AZN stock opened at $53.24 on Monday. AstraZeneca has a 1-year low of $36.15 and a 1-year high of $57.44. The stock’s fifty day moving average price is $53.45 and its 200 day moving average price is $49.67. The company has a debt-to-equity ratio of 1.32, a current ratio of 0.75 and a quick ratio of 0.57. The company has a market cap of $141.09 billion, a price-to-earnings ratio of 90.24, a price-to-earnings-growth ratio of 1.60 and a beta of 0.55.

Institutional investors have recently bought and sold shares of the business. Patriot Financial Group Insurance Agency LLC grew its stake in AstraZeneca by 223.8% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 557 shares of the company’s stock valued at $25,000 after purchasing an additional 385 shares during the last quarter. OmniStar Financial Group Inc. acquired a new position in shares of AstraZeneca in the 1st quarter valued at about $26,000. Verus Capital Partners LLC acquired a new position in shares of AstraZeneca in the 4th quarter valued at about $27,000. Golden State Wealth Management LLC acquired a new position in shares of AstraZeneca in the 1st quarter valued at about $31,000. Finally, Gemmer Asset Management LLC lifted its holdings in shares of AstraZeneca by 272.3% in the 1st quarter. Gemmer Asset Management LLC now owns 752 shares of the company’s stock valued at $34,000 after buying an additional 550 shares during the period. Institutional investors and hedge funds own 16.84% of the company’s stock.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: How does a reverse stock split work?

Earnings History and Estimates for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.